Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press24810.17650/1994-4098-2010-0-3-35-44PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯVascular endothelial growth factor inhibitors in the treatment of ovarian cancerРоль ингибиторов сосудистого эндотелиального фактора роста в лечении рака яичниковKhokhlovaS. V.ХохловаС. В.
Russian Federation
svkhokhlova@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва280820103354428082014280820142010https://ojrs.abvpress.ru/ojrs/article/view/248

Angiogenesis plays a large role in the development and spread of a number of tumors particularly in the presence of female reproductive system neoplasms. The high expression of vascular endothelial growth factor (VEGF) was found in both the primary tumor and metasta- ses and ascitic fluid in ovarian cancer (OC). Thus, the use of VEGF blockers may be effective in the treatment of OC. The most studied drug used to treat this nosological entity is bevacizumab, the high efficacy of which has been confirmed even when used as monotherapy in the patients who have received treatment many times.

Ангиогенез играет большую роль в развитии и метастазировании ряда опухолей, в особенности при опухолях женской репродуктивной системы. При раке яичников (РЯ) как в первичной опухоли, так и в метастазах и асцитической жидкости выявлен высокий уровень экспрессии сосудистого эндотелиального фактора роста (VEGF). Следовательно, использование препаратов, блокирующих VEGF, может оказаться эффективным при лечении РЯ. Наиболее изученным препаратом, применяющимся при лечении данной нозологии, является бевацизумаб, высокая эффективность которого подтверждена даже при использовании его в монотерапии у больных, получавших лечение многократно.

ovarian cancervascular endothelial growth factorinhibitorsbevacizumabрак яичниковсосудистый эндотелиальный фактор ростаингибиторыбевацизумаб1. Torry D.S., Holt V., Keenan J.A. et al. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 1996;66(1):72–80.Torry D.S., Holt V., Keenan J.A. et al. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 1996;66(1):72–80.2. Ferrara N., Chen H., Carver-Moore K. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4(3):336–40.Ferrara N., Chen H., Carver-Moore K. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4(3):336–40.3. Bausero P., Cavaille F., Meduri G. et al. Paracrine action of vascular endothelial growth factor in the human endometrium; production and target sites, and hormonal regulation. Angiogenesis 1998;2(2):167–82.Bausero P., Cavaille F., Meduri G. et al. Paracrine action of vascular endothelial growth factor in the human endometrium; production and target sites, and hormonal regulation. Angiogenesis 1998;2(2):167–82.4. Perrot-Applanat M., Ancelin M., Buteau-Lozano H. et al. Ovarian steroids in endometrial angiogenesis. Steroids 2000;65(10–11):599–603.Perrot-Applanat M., Ancelin M., Buteau-Lozano H. et al. Ovarian steroids in endometrial angiogenesis. Steroids 2000;65(10–11):599–603.5. Paley P., Goff B., Gebhard K. et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80(1):98–106.Paley P., Goff B., Gebhard K. et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80(1):98–106.6. Cooper B., Ritchie J., Broghammer C.L. et al. Preoperative serum vascular endothelial growth factor levels; significance in ovarian cancer. Clin Cancer Res 2002;8(10):3193–7.Cooper B., Ritchie J., Broghammer C.L. et al. Preoperative serum vascular endothelial growth factor levels; significance in ovarian cancer. Clin Cancer Res 2002;8(10):3193–7.7. Bozas G., Terpos E., Gika D. et al. Prechemotherapy serum levels of CD 105, TGF-ß 1⁄2, VEGF are associatedBozas G., Terpos E., Gika D. et al. Prechemotherapy serum levels of CD 105, TGF-ß 1⁄2, VEGF are associatedwith prognosis in patients with advanced epithelial ovarian cancer treated with cytopeductive surgery and platinum-based chemotherapy. Int J Gynecol Cancer 2010;20;248–54.8. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer; inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153(4):1249–56.Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer; inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153(4):1249–56.9. Burger R.A., Sill M.W., Monk B.J. et al. Phase II trial bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2007;25(33):5165–71.Burger R.A., Sill M.W., Monk B.J. et al. Phase II trial bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2007;25(33):5165–71.10. Cannistra S., Matulonis U.A., Penson R.T. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180–6.Cannistra S., Matulonis U.A., Penson R.T. et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180–6.11. EI-Shami K., Elsaid A., El-Kerm Y. Pilot trial of intraperitoneal bevacizumab as a palliative treatment in refractory malignant ascites. ASCO 2008; abstr 434.EI-Shami K., Elsaid A., El-Kerm Y. Pilot trial of intraperitoneal bevacizumab as a palliative treatment in refractory malignant ascites. ASCO 2008; abstr 434.12. Tew W.P., Colombo N., Ray Coquard I. et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer. Prelimary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25:5508 (abstr).Tew W.P., Colombo N., Ray Coquard I. et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer. Prelimary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25:5508 (abstr).13. Biagi J.J., Oza A.M., Grimshaw R. et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. NCIC GTGIND 185. J Clin Oncol 2008;26:5522 (abstr).Biagi J.J., Oza A.M., Grimshaw R. et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. NCIC GTGIND 185. J Clin Oncol 2008;26:5522 (abstr).14. Matei D., Sill M.W., DeGeest K., Bristow R.E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer. A Gynecologic Oncology group study. J Clin Oncol 2008;26:5537 (abstr).Matei D., Sill M.W., DeGeest K., Bristow R.E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer. A Gynecologic Oncology group study. J Clin Oncol 2008;26:5537 (abstr).15. Hirte H., Garcia A.A., Oza A.M. et al. A phase II of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. J Clin Oncol 2008;26(Suppl):5521 (abstr).Hirte H., Garcia A.A., Oza A.M. et al. A phase II of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. J Clin Oncol 2008;26(Suppl):5521 (abstr).16. Matulonis U.A., Kornblith A., Bryan J. et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2009;26(Suppl):5501 (abstr).Matulonis U.A., Kornblith A., Bryan J. et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2009;26(Suppl):5501 (abstr).17. Friendlander K., Hancock K.C., Benigno B. et al. Pazopanib is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers. Results of a phase II study. ASCO 2007; abstr 5561 .Friendlander K., Hancock K.C., Benigno B. et al. Pazopanib is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers. Results of a phase II study. ASCO 2007; abstr 5561 .18. Garcia A.A., Schultheis A.M., Herte H. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol 2008;26(1):76–82.Garcia A.A., Schultheis A.M., Herte H. et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer. J Clin Oncol 2008;26(1):76–82.19. Timothy A., Craig P., Stan B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167–81.Timothy A., Craig P., Stan B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167–81.20. Shirey D.R., Kavanagh J.J., Gershenson D.M. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66:575–8.Shirey D.R., Kavanagh J.J., Gershenson D.M. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66:575–8.21. Gordon A.N., Finkler N., Edwards R.P. et al. Efficacy and safety of erlotinib HCI, anepidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma. J Gynecol Cancer 2005;15:785–92.Gordon A.N., Finkler N., Edwards R.P. et al. Efficacy and safety of erlotinib HCI, anepidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma. J Gynecol Cancer 2005;15:785–92.22. Schilder R.J., Sill M.W., Chen X. et al. Phase II study of gefitinib in patients with2 relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression. A Gynecological Oncology Group study. Clin Cancer Res 2005;11:5539–48.Schilder R.J., Sill M.W., Chen X. et al. Phase II study of gefitinib in patients with2 relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression. A Gynecological Oncology Group study. Clin Cancer Res 2005;11:5539–48.23. Bookman M.A., Darcy K.M., Clarke- Pearson D. et al. Evaluation of monoclonal humanized anti-Her-2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of Her-2. J Clin Oncol 2003;21;283–90.Bookman M.A., Darcy K.M., Clarke- Pearson D. et al. Evaluation of monoclonal humanized anti-Her-2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of Her-2. J Clin Oncol 2003;21;283–90.24. Micha J.P., Goldstein B.H., Rettenmaier M.A. et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 2007;17(4):771–6.Micha J.P., Goldstein B.H., Rettenmaier M.A. et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 2007;17(4):771–6.25. Penson R., Dizon D., Cannistra S.A. et al. Phase II of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced ovarian cancer. J Clin Oncol 2010;28(1):154–9.Penson R., Dizon D., Cannistra S.A. et al. Phase II of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced ovarian cancer. J Clin Oncol 2010;28(1):154–9.26. Colombo N. Controversies in chemotherapy – what is standard treatment? Eur J Cancer 2003;1(6): 107–14.Colombo N. Controversies in chemotherapy – what is standard treatment? Eur J Cancer 2003;1(6): 107–14.27. Burger R., Brady M.F., Bookman M.A. et al. Phase III trial of bevacizumab in primary treatment of advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; A Gynecologic Oncology Group study. ASCO 2010; abstr LBA1.Burger R., Brady M.F., Bookman M.A. et al. Phase III trial of bevacizumab in primary treatment of advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer; A Gynecologic Oncology Group study. ASCO 2010; abstr LBA1.28. Guarneri V., Piacentini F., Barbieri E. et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;10:1016.Guarneri V., Piacentini F., Barbieri E. et al. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;10:1016.29. Campos S., Humphreys D. Safety of bevacizumab in advanced ovarian cancer. Clin Ovarian Cancer 2009;2(1):31–7.Campos S., Humphreys D. Safety of bevacizumab in advanced ovarian cancer. Clin Ovarian Cancer 2009;2(1):31–7.